



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 5/08, 5/06, C12P 21/02, A01K 67/027, A61K 35/39	A1	(11) International Publication Number: WO 95/29988 (43) International Publication Date: 9 November 1995 (09.11.95)
(21) International Application Number: PCT/US95/05303 (22) International Filing Date: 28 April 1995 (28.04.95) (30) Priority Data: 08/234,071 28 April 1994 (28.04.94) US (71) Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. [US/US]; 223 Grinter Hall, Gainesville, FL 32611 (US). (72) Inventors: PECK, Ammon, B.; 9311 S.W. 43rd Lane, Gainesville, FL 32608 (US). CORNELIUS, Janet, G.; 6024 N.W. 53nd Terrace, Gainesville, FL 32606 (US). (74) Agents: SALIWANCHIK, David, R. et al.; Saliwanchik & Saliwanchik, Suite A-1, 2421 N.W. 41st Street, Gainesville, FL 32606 (US).	(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i>	
(54) Title: <i>IN VITRO</i> GROWTH OF FUNCTIONAL ISLETS OF LANGERHANS AND <i>IN VIVO</i> USES THEREOF (57) Abstract <p>The subject invention concerns new methods which make it possible, for the first time, to grow functional islets in <i>in vitro</i> cultures. The subject invention also concerns the use of the <i>in vitro</i> grown islets-like structures for implantation into a mammal for <i>in vivo</i> therapy of diabetes. The subject invention further concerns a process using the <i>in vitro</i> grown islet implants for growing an organ <i>in vivo</i> that has the same functional, morphological and histological characteristics as those observed in normal pancreatic tissue. The ability to grow these cells <i>in vitro</i> and organs <i>in vivo</i> opens up important new avenues for research and therapy relating to diabetes.</p>		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DESCRIPTIONIN VITRO GROWTH OF FUNCTIONAL ISLETS OF LANGERHANS
AND IN VIVO USES THEREOF

5

Background of the Invention

Diabetes is a major public health problem. As presented in the 1987 Report of The National Long-Range Plan to Combat Diabetes commissioned by the National Diabetes Advisory Board, six million persons in the United States are known to have diabetes, and an additional 5 million have the disease which has not yet been diagnosed. Each year, more than 500,000 new cases of diabetes are identified. In 1984, diabetes was directly causal in 35,000 American deaths and was a contributing factor in another 95,000.

Ocular complications of diabetes are the leading cause of new cases of legal blindness in people ages 20 to 74 in the United States. The risk for lower extremity amputation is 15 times greater in individuals with diabetes than in individuals without it. Kidney disease is a frequent and serious complication of diabetes. Approximately 30 percent of all new patients in the United States being treated for end-stage renal disease have diabetes. Individuals with diabetes are also at increased risk for periodontal disease. Periodontal infections advance rapidly and lead not only to loss of teeth but also to compromised metabolic function. Women with diabetes risk serious complications of pregnancy. Current statistics suggest that the mortality rates for infants of mothers with diabetes is approximately 7 percent.

Clearly, the economic burden of diabetes is enormous. Each year, patients with diabetes or its complications spend 24 million patient-days in hospitals. A conservative estimate of total annual costs attributable to diabetes is at least \$24 billion (American Diabetes Association est., 1988); however, the full economic impact of this disease is even greater because additional medical expenses often are attributed to the specific complications of diabetes rather than to diabetes itself.

Diabetes is a chronic, complex metabolic disease that results in the inability of the body to properly maintain and use carbohydrates, fats, and proteins. It results from the interaction of various hereditary and environmental factors and is characterized by high blood glucose levels caused by a deficiency in insulin production or an impairment of its utilization. Most cases of diabetes fall into two clinical types: Type I, or juvenile-onset, and Type II, or adult-onset. Type I diabetes is often referred to as Insulin Dependent Diabetes, or IDD. Each type has a different prognosis, treatment, and cause.

Approximately 5 to 10 percent of diabetes patients have IDD. IDD is characterized by a partial or complete inability to produce insulin usually due to destruction of the insulin-producing β cells of the pancreatic islets of Langerhans. Patients with IDD would die without daily insulin injections to control their disease.

Few advancements in resolving the pathogenesis of diabetes were made until the mid-1970s when evidence began to accumulate to suggest that Type I IDD had an autoimmune etiopathogenesis. It is now generally accepted that IDD results from a progressive autoimmune response which selectively destroys the insulin-producing β cells of the pancreatic Islets of Langerhans in individuals who are genetically predisposed. Autoimmunity to the β cell in IDD involves both humoral (Baekkeskov *et al.*, 1982; Baekkeskov *et al.*, 1990; Reddy *et al.* 1988; Pontesilli *et al.*, 1987) and cell-mediated (Reddy *et al.* 1988; Pontesilli *et al.*, 1987; Wang *et al.*, 1987) immune mechanisms. Humoral immunity is characterized by the appearance of autoantibodies to β cell membranes (anti-69 kD and islet-cell surface autoantibodies), β cell contents (anti-carboxypeptidase A₁, anti-64 kD and/or anti-GAD autoantibody), and/or β cell secretory products (anti-insulin). While serum does not transfer IDD, anti- β cell autoantibody occurs at a very early age, raising the question of an environmental trigger, possibly involving antigenic mimicry. The presence of cell-mediated immunological reactivity in the natural course of IDD is evidenced by an inflammatory lesion within the pancreatic islets, termed insulinitis. Insulinitis, in which inflammatory/immune cell infiltrates are clearly visible by histology, has been shown to be comprised of numerous cell types, including T and B lymphocytes, monocytes and natural killer cells (Signore *et al.*, 1989; Jarpe *et al.* 1991). Adoptive transfer experiments using the NOD (non-obese diabetic) mouse as a model of human IDD have firmly established a primary role for auto-aggressive T lymphocytes in the pathogenesis of IDD (Bendelac, *et al.*, 1987; Miller *et al.*, 1988; Hanafusa *et al.*, 1988; Bendelac *et al.*, 1988). Unfortunately, the mechanisms underlying destruction of the pancreatic β cells remain unknown.

Numerous strategies (e.g., bone marrow replacement, immunosuppressive drugs and autoantigen immunizations) have been investigated as possible means to arrest the immunological attack against the pancreatic β cells. However, for these approaches to be effective, individuals who will eventually develop clinical disease must be identified. Most often, patients are identified too late for effective intervention therapy since the immunological attack has progressed to a point where a large percentage of the β cells have already been destroyed. Because the β cell is thought to be an end-stage differentiated cell, it is believed that the body has little capacity to regenerate new β cells, thus necessitating regular life-long insulin therapy. Recently, one approach to overcome this problem has been islet cell transplantation. Islet cell transplantation has the disadvantage that the islets are allogeneic which, in turn, can invoke an allo-immune response. Thus, there would be major advantages to growing Islets of Langerhans containing functional β cells directly from IDD patients.

Brief Summary of the Invention

The subject invention concerns the discovery that functional islets containing insulin-producing β cells, as well as other islet cell types, can be grown in long-term cultures from single pluripotent stem cells.

5 The novel methods of the subject invention take advantage of the discovery that pluripotent stem cells exist even in the pancreas of adult individuals. The cells can be cultured in a high amino acid nutrient medium that is supplemented with normal serum which is preferably derived from the same mammalian species which serves as the origin of the islet cells (homologous serum). This culture is then left undisturbed for several weeks to permit
10 establishment of stromal cells. Once this stromal cell layer is mature, cell differentiation can be initiated by refeeding the cell culture with the high amino acid medium supplemented with homologous normal serum plus glucose. After an additional period of growth, functional islets containing cells which produce insulin, glucagon, somatostatin and other endocrine hormones can then be recovered using standard techniques.

15 It was not previously known or suspected that pancreatic cells could be used to grow new islet cells, including β cells, in culture. The fortuitous discovery of culture techniques for growing islet-like tissue *in vitro* eliminates what had previously been a substantial and long standing barrier to diabetes research. The novel methods and materials described herein will enable a better understanding of the mechanisms of diabetes. Furthermore, the ability to grow islet cells in culture
20 will now make certain therapies for diabetes possible for the first time. For example, in accordance with the subject invention, new cultured islets from diabetic individuals can be implanted in a patient as a way to control or eliminate the patient's need for insulin therapy because the cultured islets and/or islet cells are able to produce insulin *in vivo*. Thus, the subject invention also concerns the use of the *in vitro* grown islets of the subject invention for
25 implantation into a mammalian species for *in vivo* treatment of IDD.

The subject invention also greatly facilitates genetic engineering of islet cells to resist subsequent immunological destruction. For example, the cultured islet cells can be transformed to express a protein or peptide which will inhibit or prevent the destructive immune process. Other useful proteins or peptides may be expressed.

30 Thus, the ability to grow functioning islets *in vitro* from the pancreatic cells of an individual represents a major technical breakthrough and facilitates the use of new strategies for treating IDD. The discovery that pluripotent stem cells exist in adult pancreas circumvents the need to use fetal tissue as a source of cells.

35 The subject invention also concerns the islet cells produced *in vitro* according to the methods described herein. These cells can be produced from a mammalian pancreatic cell suspension cultured *in vitro* and can give rise to functional islet cells and islet-like tissue structures.

The subject invention further concerns the *in vitro* growth, propagation and differentiation of a pancreatic stem cell, *i.e.*, a progenitor cell or cells that can give rise to the formation of all of the different types of cells and tissue that make up a normal pancreas. Moreover, the subject invention concerns the *in vivo* use of *in vitro* grown pancreatic stem cells to produce an "ecto-pancreas" organ that exhibits functional, morphological and histological characteristics similar to those observed in a normal pancreas. Thus, the ability to produce a functional "ecto-pancreas" *in vivo* from *in vitro* grown pancreatic cells can be used to treat, reverse or cure a wide variety of pancreatic diseases that are known to result in damage or destruction of the pancreas.

Brief Summary of the Figures

Figures 1A through 1D show cells grown according to the procedures of the subject invention.

Figure 2 shows an islet grown according to the subject invention.

Detailed Description of the Invention

According to the subject invention, functional Islets of Langerhans can for the first time be grown in *in vitro* cultures. The techniques of the subject invention result in cell cultures which can produce insulin, glucagon, somatostatin or other endocrine hormones. Other useful proteins may also be produced by, for example, transforming the islet cell with DNA which encodes proteins of interest. The ability to grow these functional cell cultures enables those skilled in the art to carry out procedures which were not previously possible.

The method of the subject invention involves making suspensions of stem cells from the pancreas of a mammal. Preferably, the stem cells would be from the pancreas of a prediabetic mammal. However, it is also contemplated that cells from mammals already showing clinical signs of diabetes can be utilized with the subject invention. The cell suspensions are prepared using standard techniques. The cell suspension is then cultured in a nutrient medium that facilitates the growth of the cells. In a preferred embodiment, the nutrient medium is one which has a high concentration of amino acids. One such medium is known as Click's EHAA medium and is well known and readily available to those skilled in the art. Other equivalent nutrient mediums could be prepared and utilized by those skilled in the art. The medium used to suspend the islet cells is advantageously supplemented with normal serum from the same species of mammal from which the islet cells originate. Thus, in the case of mouse islets the medium is supplemented with normal mouse serum, whereas in the case of human islet cells the medium is supplemented with normal human serum. The preparation of normal serum is well known to those skilled in the art. The concentration of normal serum used with the cell culture method of the subject invention can range from about 0.5% to about 10%, but for mice is preferably about 1%. For human serum, a higher concentration is preferred, for example, about 5%.

The cell suspension prepared in the nutrient medium supplemented with normal serum is then incubated under conditions that facilitate cell growth, preferably at about 35-40° C and, preferably, in about 5% CO₂ atmosphere. This incubation period is, thus, carried out utilizing standard procedures well known to those skilled in the art. The cell culture is then preferably left undisturbed without feeding for several weeks. Preferably, the cultures are not disturbed for at least about 3 weeks. During this time stromal cells proliferate and establish a monolayer which will ultimately give rise to islet cells. The initiation of cellular differentiation can be brought about by refeeding the cultures with Click's EHAA medium supplemented with normal serum as discussed above. Rapid refeeding was found to induce extensive islet foci formation with considerable cell differentiation. Upon histological examination of the cells in the islet-like structures, at least three distinct cell types were identifiable and appeared similar to islet cells prepared from islets of control mice. The time required for cell differentiation to occur within these foci decreased as the frequency of refeeding was increased.

We have been able to propagate and expand islet-producing cultures through the serial transfer of islet-derived stromal cells plus islet foci to new culture flasks. This facilitates generating sufficient numbers of islets as required for use in methods described herein for, for example, reversing the metabolic problems of IDD.

In order to determine whether the islet-like structures and/or islet cells produced *in vitro* according to the subject invention could reverse IDD, the islet-like structures were implanted into NOD mice. Mice that received the islet implants exhibited a reversal of insulin-dependent diabetes, whereas untreated NOD mice showed signs of clinical disease. In addition, no autoimmune pathogenesis was observed during the duration of the implants. Thus, islet implants of the subject invention can be used *in vivo* to treat diabetes in mammals, including humans.

In a preferred embodiment of the subject invention, the progression of diabetes can be slowed or halted by reimplantation of autologous islets engineered to be resistant to specific factors involved in the immunological attack. For example, the islets can be engineered so that they are resistant to cytotoxic T cell-derived interferon- γ . The availability of long-term cultures of whole islets can also be used in investigations into the pathogenesis of IDD, including the cellular recognition of β cells, the mode of islet infiltration, and the immune mechanisms of β cell destruction. Furthermore, this technology will facilitate islet transplantation, autologous islet replacement, and even development of artificial islets. The growth of these cells according to the procedures of the subject invention has great utility in teaching students important aspects relating to cell differentiation and function.

In a further embodiment of the subject invention, pluripotent pancreatic stem cells have been grown *in vitro* from pancreas cells isolated from a mammal. A surprising discovery using these *in vitro* grown cells in conjunction with the methods of the subject invention was the ability to grow and produce, *in vivo*, an organ that exhibited functional, morphological and histological

endocrine and exocrine tissues. The ecto-pancreas (a pancreas-like organ situated at an abnormal site within the body cavity) produced *in vivo* according to the subject invention represents a major scientific discovery and provides a novel means for studying, treating, reversing or curing a number of pancreas-associated pathogenic conditions.

5 As used herein, the term "growth" refers to the maintenance of the cells in a living state, and may include, but is not limited to, the propagation and/or differentiation of the cells. The term "propagation" refers to an increase in the number of cells present in a culture as a result of cell division.

10 Following are examples which illustrate procedures, including the best mode, for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

Example 1 - Culturing of Functional Islets of Langerhans

15 Single cell suspensions of islet cells were prepared from whole islets isolated from the pancreas of 19-20 week old prediabetic male NOD/UF mice, as detailed elsewhere (Shieh *et al.*, 1993). Typically, about 25% of the male mice in a NOD colony will have overt IDD at this age and all will have severe insulinitis. The islet cells were resuspended in Click's EHAA medium supplemented with normal mouse serum (NMS) to 1% (Peck and Bach, 1973; Peck and Click, 1973), plated in a 25 cm² tissue culture flask, and incubated at 37° C in a 5% CO₂ atmosphere.

20 At this stage, two outcomes are possible: first, the islet-infiltrating cells may dominate, thus permitting the establishment of immune cell lines, or second, stromal-like cells may dominate, thus allowing the growth of a "nurse cell" monolayer. Growth of stromal-like cell monolayers appeared to result when islet-infiltrating cells were plated simultaneously but in limited numbers. Enrichment of the islet cells with decreased numbers of infiltrating cells can be achieved by

25 gradient separation (Jarpe *et al.*, 1991). Stromal cell cultures, when left undisturbed for 4-5 weeks (i.e., no refeeding) proliferated to cover the entire bottom surface of the culture vessel. From this monolayer of cells, small rounded cells appeared almost as if budding from the stromal cell layer.

 Differentiation of the cultures was initiated by refeeding the cultures with Click's EHAA medium supplemented with NMS and a sugar solution comprising glucose or sucrose or other sugar equivalents. Typically, the sugar is glucose. The concentration of glucose can be between

30 about 10 mM to 25 mM, but typically is between 15 and 17 mM. Preferably, the concentration of glucose in the medium is approximately 16 mM. Techniques for refeeding cell cultures *in vitro* are well known in the art and typically involve removing from about 50% to about 90% of the old nutrient medium and adding fresh medium to the culture flask. Rapid refeeding induced the

35 formation of increasing numbers of centers of islet growth (referred to herein as foci) exhibiting cell differentiation. The rate of refeeding can be, for example, at about one week intervals. Preferably, the rate of refeeding is at about 5 to 6 day intervals.

At peak production, as many as 150-200 foci occurred simultaneously in a single 25 cm² tissue culture flask. As the cell proliferation and differentiation proceeded, the organization of the islet took place and the islet even appeared to surround itself in a capsular material. The islets generally grew to a constant size (although several grew to about twice the general size), then detached off of the stromal layers to float in the medium. These free-floating islets tended to break down within 48-72 hours, similar to isolated pancreatic islets cultured under similar conditions.

The islet-like structures, collected after natural detachment or removal from the stromal layers using a pasteur pipette, were gently washed in medium, then broken into single cell suspensions by reflux pipetting. Single cell suspensions were prepared by cytocentrifugation, then stained for general morphology and insulin production. The foci contained cells producing the endocrine hormones glucagon (α cells), insulin (β cells) and/or somatostatin (δ cells). Furthermore, the major population of cells stained positive with anti-insulin antibody, indicating the major cell type contained in the cultured islet is an insulin-producing β cell. Figures 1A through 1D show the various cell types which develop during the culture process. Figure 2 shows a well-developed islet obtained after the *in vitro* culture of cells according to the method of the subject invention.

Example 2 - Culturing of Human Islet Cells

For culturing human islet cells, a procedure similar to that described in Example 1 was utilized. The procedure of the subject invention is particularly advantageous because it is not necessary to utilize fetal cells to initiate the cell culture. In a preferred embodiment, the human cells can be suspended in Click's EHAA medium (or the equivalent thereof) supplemented with normal human serum. Preferably, the concentration of normal human serum used in the medium is about 5%. The cultures should be left undisturbed with no refeeding, preferably for several weeks. After about 4-5 weeks in culture, cell differentiation can be initiated by refeeding the cultures with Click's EHAA medium supplemented with normal human serum and glucose as described in Example 1. Islet-like structures can subsequently be collected and single cell suspensions prepared for further propagation as described in Example 1.

Example 3 - Implantation of *in vitro* Grown Islet Cells

To test the efficacy of these *in vitro* generated islet-like structures to reverse the complications of IDD, approximately 150-200 foci plus some stromal cells grown *in vitro* according to the method of the subject invention from pancreatic tissue of NOD mice were dislodged from the tissue culture flask by reflux pipetting. The cells were then implanted beneath the kidney capsule of syngeneic diabetic NOD mice maintained by daily insulin injections. Implantation was accomplished by puncturing the kidney capsule with a hypodermic needle, threading a thin

the cortex region. The capillary tube was carefully withdrawn and the puncture site cauterized. The surgical incision of each implanted mouse was clamped until the skin showed signs of healing. The implanted mice were maintained on insulin injections for 4 days at the full daily dosage, and then for 2 days at the half daily dosage, after which the mice were completely weaned from further insulin treatment. Control animals consisted of diabetic NOD mice that did not receive an implant.

Control NOD mice, when removed from daily injections of insulin, showed a rapid onset of overt disease, including lethargy, dyspnea, weight loss, increased blood glucose levels, wasting syndrome, failure of wound healing and death within three weeks. Implanted NOD mice maintained a blood glucose level of about 180 mg/dl (which is slightly above the normal range for mice), showed increased activity, rapid healing of surgical and blood-draw sites, did not develop dyspnea, and remained healthy until killed for histological studies. Similar observations haven been seen with intra-splenic implants.

Example 4 - *In vivo* Production of Ecto-Pancreas

Histological examinations of the implant sites in mice that were implanted with the islet cells as described in Example 3 revealed an additional characteristic of the *in vitro* generated islet-forming stem cells. Implanted cells which "leaked" from the implant site of the kidney underwent additional proliferation and differentiation and formed a highly structured ecto-pancreas. At first, the ecto-pancreatic tissue consisted entirely of proliferating exocrine cells which organized into an exocrine pancreas complete with innervating blood vessels. This exocrine pancreas progressed to form islet-like endocrine structures. Thus, the *in vitro* cell cultures produced according to the methods of the subject invention contain pluripotent pancreatic stem cells capable of regenerating a completely new pancreas. The growth of a pancreas containing both exocrine and endocrine tissue provides new methods for treatment of pancreatic diseases, including pancreatitis and pancreatic cancer.

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

References

- Eisenbarth, G.S., (1986) *N. Engl. J. Med.* 314:1360.
- Cahil, G.F., and H.O. McDevitt (1981) *N. Engl. J. Med.* 304:1454.
- Todd JA, J.A., *et al.* (1989) *Nature* 338:587.
- Prochazka, M., D.V. Serreze, S.M. Worthen, and E.H. Leiter (1989) *Diabetes* 38:1446.
- Baekkeskov, S., *et al.*, (1982) *Nature* 298:167.
- Baekkeskov, S., *et al.* (1990) *Nature* 347:151.
- Reddy, S., N.J. Bibby, and R.B. Elliot (1988) *Diabetologia* 31:322.
- Pontesilli, O., P. Carotenuto, L.S. Gazda, P.F. Pratt, and S.J. Prowse (1987) *Clin. Exp. Immunol.* 70:84.
- Wang, Y., L. Hao, R.G. Gill, and K.J. Lafferty (1987) *Diabetes* 36:535.
- Karjalainen *et al.* (1992) *N. Engl. J. Med.* 327:302.
- Serreze, D.V., E.H. Leiter, E.L. Kuff, P. Jardieu, and K. Ishizaka (1988) *Diabetes* 37:351
- Signore, A., P. Pozzilli, E.A.M. Gale, D. Andreani, and P.C.L. Beverly (1989) *Diabetologia* 32:282.
- Jarpe, A.J., M. Hickman, J.T. Anderson, W.E. Winter, and A.B. Peck (1991) *Regional Immunol.* 3:305
- Bendelac, A., C. Carnaud, C. Boitard, and J.F. Bach (1987) *J. Exp. Med.* 166:823.
- Miller, B.J., M.C. Appel, J.J. O'Neil, and L.S. Wicker (1988) *J. Immunol.* 140:52.
- Hanafusa T. *et al.* (1988) *Diabetes* 37:204.
- Bendelac A. *et al.* (1988) *J. Immunol.* 141:2625.
- Rossini, A.A., J.P. Mordes, and E.S. Handler (1988) *Diabetes* 37:257.
- Nerup, J., *et al.* (1989) *Diabetes Care* 11:16.
- Kanazawa, Y., *et al.* (1984) *Diabetologia* 27:113.
- Anderson, J.T., J.G. Cornelius, A.J. Jarpe, W.E. Winter and A.B. Peck (1993) *Autoimmunity* 15:113.
- Shieh, D.C., J.G. Cornelius, W.E. Winter, and A.B. Peck (1993) *Autoimmunity* 15:123.
- Peck, A.B. and F.H. Bach (1973) *J. Immunol. Methods* 3:147.
- Peck, A.B. and R.E. Click (1973) *European J. Immunology* 3:382.

Claims

- 1 1. A method for the *in vitro* growth of stem cells which comprises culturing islet cells
2 from a mammalian species in a nutrient medium supplemented with normal serum, allowing said islet
3 cells to grow for at least about 3 weeks, and initiating cellular differentiation into mature islet cells
4 by refeeding said islet cell culture with a nutrient medium supplemented with normal serum.
- 1 2. The method, according to claim 1, wherein the islet cells are human islet cells and
2 the serum is normal human serum.
- 1 3. The method, according to claim 1, wherein the islet cells are mouse islet cells and the
2 serum is normal mouse serum.
- 1 4. A method, according to claim 1, wherein said nutrient medium comprises a high
2 amino acid nutrient medium.
- 1 5. The method, according to claim 1, wherein the culture medium used to refeed said
2 cell culture further comprises glucose.
- 1 6. The method, according to claim 1, wherein differentiation of cultured stem cells is
2 initiated at about 4 to 5 weeks of culture growth by refeeding of said islet cell culture with the nutrient
3 medium supplemented with homologous normal serum.
- 1 7. The method, according to claim 1, wherein after cell differentiation is initiated by
2 refeeding the culture, the culture is refed at about one-week intervals
- 1 8. An islet cell produced by the method of claim 1.
- 1 9. The method, according to claim 1, wherein islet-like tissue is produced after
2 differentiation of said islet cells.
- 1 10. The method, according to claim 1, wherein the normal serum is obtained from the
2 same mammalian species from which the islet cells were obtained.
- 1 11. An islet-like tissue structure produced by the method of claim 9.
- 1 12. A method for producing an endocrine hormone wherein said method comprises
2 culturing islet cells from a mammalian species in a nutrient medium supplemented with normal serum,

3 allowing said islet cells to grow for at least about 3 weeks, and initiating cellular differentiation by
4 refeeding said islet cell culture with a nutrient medium supplemented with normal serum, and
5 recovering said endocrine hormone from said islet cell culture.

1 13. The method, according to claim 12, wherein said hormone is a human hormone.

1 14. The method, according to claim 12, wherein said hormone is a mouse hormone.

1 15. The method, according to claim 12, wherein differentiation is initiated at about 4 to
2 5 weeks of culture growth by refeeding of said islet cell culture with said nutrient medium
3 supplemented with normal serum.

1 16. The method, according to claim 12, wherein said endocrine hormone is selected from
2 the group consisting of insulin, glucagon and somatostatin.

1 17. A method for producing a pancreas-like organ in a mammal which comprises
2 implanting an islet or an islet cell produced by the method of claim 1 into the tissue of the mammal.

1 18. A method for treating pancreatic disease in a mammal which comprises producing
2 a pancreatic-like organ in the mammal *in vivo* according to the method of claim 17.

1 19. A pancreas-like organ produced according to the method of claim 17.

1 20. The method, according to claim 1, wherein the mature islet cells comprise cells
2 selected from the group consisting of α cells, β cells and δ cells.

1 21. The method, according to claim 17, wherein said islet or islet cell implanted into the
2 mammal is autologous to the mammal receiving the implant.

1 22. The method, according to claim 17, wherein the mammal is a human.

1 23. The pancreas-like organ, according to claim 19, wherein said organ is produced in a
2 human.

1 24. A mammal having a pancreas-like organ produced according to the method of claim
2 17.

1 25. A mammal, according to claim 24, wherein said mammal is a mouse.




Figure 1A




Figure 1B




Figure 1C




Figure 2




Figure 1D

INTERNATIONAL SEARCH REPORT

 Intern. Application No
 PCT/US 95/05303

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N5/08 C12N5/06 C12P21/02 A01K67/027 A61K35/39

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K C12P A01K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 77, no. 6, June 1980 WASHINGTON US, pages 3519-3523, GAZDAR A.F. ET 'Continuous, clonal, insulin- and somastostatin-secreting cell lines established from a transplantable rat islet cell tumor' see the whole document ---	1, 12, 17
X	WO,A,93 00441 (PACIFIC BIOMEDICAL RESEARCH) 7 January 1993 see the whole document ---	1, 12, 17
-/--		

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

26 July 1995

Date of mailing of the international search report

1 0. 08. 95

Name and mailing address of the ISA

 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

Moreau, J

INTERNATIONAL SEARCH REPORT

Inter. Application No

PCT/US 95/05303

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>UPSALA J MED SCI 98 (1). 1993. 39-52. CODEN: UJMSAP ISSN: 0300-9734, KORSGREN O ET AL 'IN-VITRO SCREENING OF PUTATIVE COMPOUNDS INDUCING FETAL PORCINE PANCREATIC BETA-CELL DIFFERENTIATION IMPLICATIONS FOR CELL TRANSPLANTATION IN INSULIN -DEPENDENT DIABETES MELLITUS.' see the whole document ---</p>	1,12, 17-25
A	<p>WO,A,86 01530 (NORDISK GENTOFTE) 13 March 1986 see the whole document ---</p>	1-16
A	<p>ENDOCRINOLOGY, vol. 111, no. 5, November 1982 pages 1568-1575, MCEVOY R.C. ET AL. 'Tissue Culture of Fetal Rat Islets ...' see the whole document ---</p>	1-11
A	<p>EP,A,0 363 125 (HANA BIOLOGICS INC.) 11 April 1990 see the whole document ---</p>	1-11
P,X	<p>WO,A,94 23572 (HUMAN CELL CULTURES, INC.) 27 October 1994 see the whole document -----</p>	1,12,17

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/05303

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 18 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/compositon.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/05303

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9300441	07-01-93	AU-A- 2228592	25-01-93
		CA-A- 2112112	07-01-93
		EP-A- 0605428	13-07-94
		JP-T- 6508527	29-09-94

WO-A-8601530	13-03-86	AU-A- 4805185	24-03-86
		EP-A- 0190337	13-08-86

EP-A-363125	11-04-90	JP-A- 2200178	08-08-90

WO-A-9423572	27-10-94	AU-B- 6413994	08-11-94

THIS PAGE BLANK (USPTO)

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**

THIS PAGE BLANK (USPTO)